GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,648 | 2,767 | 2,045 | 5,672 | 2,465 |
| Marketable Securities | 13,366 | 15,206 | 17,854 | 10,836 | 18,319 |
| TOTAL | $16,052 | $18,021 | $19,937 | $16,562 | $20,872 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 96 | 123 | 149 | 174 | 199 |
| TOTAL | $96 | $123 | $149 | $174 | $199 |
| Total Assets | $16,148 | $18,144 | $20,086 | $16,736 | $21,071 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,970 | 3,501 | 3,131 | 3,140 | 3,325 |
| Accrued Expenses | 1,028 | 1,222 | 829 | 1,669 | 1,537 |
| Other current liabilities | N/A | N/A | N/A | 19 | 57 |
| TOTAL | $5,090 | $4,843 | $4,076 | $4,938 | $5,025 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,053 | 1,538 | 2,957 | 64 | 92 |
| TOTAL | $1,053 | $1,538 | $2,957 | $64 | $92 |
| Total Liabilities | $6,143 | $6,381 | $7,033 | $5,002 | $5,117 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,379 | 1,353 | 1,247 | 1,226 | 1,084 |
| Common Shares | 42 | 41 | 37 | 33 | 33 |
| Retained earnings | -679,103 | -676,687 | -674,695 | -674,468 | -668,884 |
| Other shareholders' equity | 1 | 1 | 1 | 1 | 1 |
| TOTAL | $10,005 | $11,763 | $13,053 | $11,734 | $15,954 |
| Total Liabilities And Equity | $16,148 | $18,144 | $20,086 | $16,736 | $21,071 |